Compare · NVO vs ONC
NVO vs ONC
Side-by-side comparison of Novo Nordisk A/S (NVO) and BeOne Medicines Ltd. (ONC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ONC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 5.0x ONC ($42.79B).
- ONC has been more active in the news (11 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 7 for ONC).
- Company
- Novo Nordisk A/S
- BeOne Medicines Ltd.
- Price
- -
- -
- Market cap
- $215.46B
- $42.79B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 9
- 11
- Recent ratings
- 25
- 7
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest ONC
- BeOne Medicines Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
- SVP, General Counsel Lee Chan Henry exercised 2,666 units of American Depositary Shares at a strike of $191.37 and sold $959,760 worth of American Depositary Shares (2,666 units at $360.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Oyler John sold $86,480,472 worth of American Depositary Shares (240,810 units at $359.12) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- SEC Form 144 filed by BeOne Medicines Ltd.
- BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
- Chief Financial Officer Rosenberg Aaron sold $361,811 worth of American Depositary Shares (1,157 units at $312.71), closing all direct ownership in the company (SEC Form 4) to satisfy tax liability
- SEC Form 10-Q filed by BeOne Medicines Ltd.
- BeOne Medicines Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates